$18.82
-6.8%Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
KMTS • NASDAQ
| Kestra Medical Technologies, Ltd. Cash Flow Statement | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2021 | Apr 2020 |
|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||
-113.8M | -94.1M | -84.2M | -34.1M | -29.5M | |
8M | 11.6M | 4.9M | 420K | 478K | |
64K | 12K | -45K | 0.0 | 0.0 | |
24.3M | 1.5M | 1.2M | 1.9M | 0.0 | |
10.1M | 4.4M | 7.3M | 1.9M | 706K | |
(0.0) | (43K) | (12K) | (214K) | (70K) | |
-6.2M | 4.4M | 1.3M | -19K | -2M | |
-77.6M | -72.2M | -69.6M | -29.9M | -30.3M | |
INVESTING ACTIVITIES | |||||
-23.6M | -12.5M | -15.5M | -336K | -232K | |
283K | 285K | 0.0 | 2K | 0.0 | |
-23.3M | -12.2M | -15.5M | -334K | -232K | |
FINANCING ACTIVITIES | |||||
215.8M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 5.9M | -5.3M | 20M | 0.0 | |
-1.7M | -799K | -671K | -187K | -183K | |
12.7M | -2.4M | 0.0 | 29M | 30.4M | |
330.3M | 77.7M | 96.1M | 48.8M | 30.2M | |
CASH FLOW SUMMARY | |||||
229.3M | -6.7M | 11M | 18.6M | -286K | |
8.6M | 15.3M | 4.3M | 6.3M | 6.6M | |
237.9M | 8.6M | 15.3M | 24.9M | 6.3M | |
-101.2M | -84.7M | -85.1M | -30.2M | -30.5M |
KMTS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | March 17, 2026 | January 31, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 11, 2025 | December 11, 2025 | 2025 | |
10-Q 10-Q 2025 Q4 Q4 | December 11, 2025 | October 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 04, 2025 | December 02, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 01, 2025 | December 01, 2025 | 2025 | |
S-1 S-1 N/A | December 01, 2025 | December 01, 2025 | ||
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | September 12, 2025 | July 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 11, 2025 | September 11, 2025 | 2025 |
Continue your KMTS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.